GTC Biotherapeutics (fka GTCB)

[DewDiligence]

U.S. ATryn Development Timeline for HD Indication

[Based on GTC’s 7-Jan-2008 PR (#msg-25781631).]

January 2008: Complete study; report top-line results; begin “rolling” BLA submission.

1Q08 (presumably after the reporting of top-line data): Announce partnership for HD indication and AD indication(s).

2Q08: Report antibody data to FDA; complete data analysis.

Mid 2008: Submit final module of BLA.

Late 2008/early 2009: FDA decision on BLA (assuming a six-month priority review).